Effect of cetiedil on platelet aggregation and thromboxane synthesis.
Cetiedil was found to inhibit platelet aggregation and thromboxane synthesis induced by thrombin and arachidonic acid. When platelets were activated by thrombin, half maximal inhibition (ED50 effective dose of cetiedil necessary for 50% inhibition) for platelet aggregation was 100 microM while that for thromboxane B2 (TXB2) production was 50 microM. When arachidonic acid was used, the ED50 for platelet aggregation was 100 microM while that for TXB2 production was 150 microM. The presence of calcium ions did not affect on the inhibitory effects of cetiedil. The cAMP level in platelets did not increase after incubation with cetiedil. Cetiedil appears to inhibit the activation of platelets related to thromboxane synthesis.
Yamaguchi
A
A
Asakura
T
T
Tanoue
K
K
Yamazaki
H
H
D000986:Antisickling Agents; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000494:pharmacology; D000242:Cyclic AMP / Q000097:blood; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects*; D013917:Thrombin / Q000494:pharmacology; D013929:Thromboxane B2 / Q000097:blood*; D013931:Thromboxanes / Q000097:blood*
D000986:Antisickling Agents; D001095:Arachidonic Acids; D001381:Azepines; D013931:Thromboxanes; D016718:Arachidonic Acid; D013929:Thromboxane B2; C006955:cetiedil; D000242:Cyclic AMP; D007770:L-Lactate Dehydrogenase; D013917:Thrombin; D002118:Calcium